Capital Impact Advisors, LLC Castle Biosciences Inc Transaction History

Capital Impact Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$18.06 - $25.3 $111,231 - $155,822	6,159 Added 37.21%	22,713 $503,000
Q2 2023 Aug 14, 2023	BUY	$11.66 - $26.0 $12,849 - $28,652	1,102 Added 7.13%	16,554 $227,000
Q4 2022 Feb 14, 2023	BUY	$18.08 - $30.0 $18,025 - $29,910	997 Added 6.9%	15,452 $363,000
Q3 2022 Nov 21, 2022	BUY	$22.51 - $34.32 $10,917 - $16,645	485 Added 3.47%	14,455 $289,000
Q2 2022 Aug 15, 2022	SELL	$16.0 - $45.99 $56,976 - $163,770	-3,561 Reduced 20.31%	13,970 $307,000
Q1 2022 May 16, 2022	SELL	$33.17 - $46.98 $228,806 - $324,068	-6,898 Reduced 28.24%	17,531 $786,000
Q4 2021 Feb 14, 2022	BUY	$39.06 - $67.58 $301,777 - $522,123	7,726 Added 46.26%	24,429 $1.05 Million
Q3 2021 Nov 15, 2021	BUY	$60.13 - $77.6 $210,455 - $271,600	3,500 Added 26.51%	16,703 $1.11 Million
Q2 2021 Aug 17, 2021	BUY	$50.07 - $76.78 $559,382 - $857,786	11,172 Added 550.07%	13,203 $968,000
Q1 2021 May 18, 2021	SELL	$58.92 - $97.33 $1.35 Million - $2.24 Million	-22,969 Reduced 91.88%	2,031 $139,000
Q4 2020 Feb 12, 2021	BUY	$43.6 - $73.05 $1.09 Million - $1.83 Million	25,000 New	25,000 $1.68 Million

171

25.5M

511K

130K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $750M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.